# WINREVAIR (sotatercept) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sotatercept

> The next catalyst for WINREVAIR (sotatercept), sponsored by Merck & Co., Inc. (MRK), is its topline data readout, Jun to Sep 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | WINREVAIR (sotatercept) |
| Codes | MK-7962, ACE-011 |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | [Pulmonary Arterial Hypertension](https://sec-api.dev/indications/pulmonary-arterial-hypertension), [Pulmonary Hypertension](https://sec-api.dev/indications/pulmonary-hypertension) |
| Modality | fusion_protein |
| FDA designations | priority review |

## Timeline

### Nov 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2025-02-25, last confirmed 2025-02-25.
- SEC Form 10-K (accession 0001628280-25-007732): "In November 2024, Merck announced positive topline results from the Phase 3 ZENITH study, evaluating Winrevair in adults with PAH with WHO Group 1 FC III or IV at high risk of mortality." https://www.sec.gov/Archives/edgar/data/310158/000162828025007732/mrk-20241231.htm

### Jan 2025: interim data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2025-02-25, last confirmed 2025-02-25.
- SEC Form 10-K (accession 0001628280-25-007732): "In addition, in January 2025, Merck announced the Phase 3 HYPERION study evaluating Winrevair in newly diagnosed adults with PAH FC II or III at intermediate or high risk of disease progression was also stopped early based on the positive results from the interim analysis of the ZENITH trial and a review of the totality of data from the Winrevair clinical program to date." https://www.sec.gov/Archives/edgar/data/310158/000162828025007732/mrk-20241231.htm

### October 25, 2025: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2025-07-29, last confirmed 2025-08-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-071380): "FDA Granted Priority Review for WINREVAIR to Update Label Based on Results From ZENITH Trial; FDA Set PDUFA Date of Oct. 25, 2025" https://www.sec.gov/Archives/edgar/data/310158/000110465925071380/tm2521736d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-071380): "The FDA has set a PDUFA date of Oct. 25, 2025." https://www.sec.gov/Archives/edgar/data/310158/000110465925071380/tm2521736d1_ex99-1.htm
- SEC Form 10-Q (accession 0000310158-25-000014): "The FDA set a PDUFA date of October 25, 2025." https://www.sec.gov/Archives/edgar/data/310158/000031015825000014/mrk-20250630.htm

### November 20, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Pulmonary Arterial Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06664801 (A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-20 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06664801

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Pulmonary Arterial Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06925750 (A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-06-16 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06925750

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Pulmonary Arterial Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06925750 (A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-06-16 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06925750

### Sep to Dec 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Pulmonary Arterial Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05587712 (Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-21 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05587712

### September 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Pulmonary Arterial Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05587712 (Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-21 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05587712

### Dec 2028 to Mar 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Pulmonary Arterial Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07218029 (A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-12-07 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07218029

### December 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Pulmonary Arterial Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07218029 (A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-12-07 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07218029

### May to Aug 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Pulmonary Arterial Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07646860 (A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07646860

### May 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Pulmonary Arterial Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07646860 (A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07646860

### Jan to Apr 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Pulmonary Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07839585 (A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-01-08 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07839585

### January 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Pulmonary Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07839585 (A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-01-08 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07839585

## Same indication

- [Frespaciguat](https://sec-api.dev/pdufa/frespaciguat) (MRK)
- [Gb002 (seralutinib)](https://sec-api.dev/pdufa/gb002-seralutinib) (GOSS)
- [IKT-001](https://sec-api.dev/pdufa/ikt-001) (IKT)
- [Opsumit (macitentan)](https://sec-api.dev/pdufa/macitentan) (JNJ)
- [PF-07868489](https://sec-api.dev/pdufa/pf-07868489) (PFE)
- [TNX-103](https://sec-api.dev/pdufa/tnx-103) (TENX)
- [Treprostinil palmitil](https://sec-api.dev/pdufa/treprostinil-palmitil) (INSM)
- [Treprostinil palmitil inhalation powder](https://sec-api.dev/pdufa/treprostinil-palmitil-inhalation-powder) (INSM)
- [Tx000045- dose a](https://sec-api.dev/pdufa/tx000045) (TECX)

Calendar months: [October 2025](https://sec-api.dev/fda-calendar/2025-10), [June 2028](https://sec-api.dev/fda-calendar/2028-06), [September 2028](https://sec-api.dev/fda-calendar/2028-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sotatercept.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "WINREVAIR (sotatercept) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sotatercept

```bibtex
@misc{secapidev_pdufa_sotatercept_20261116,
  title        = {WINREVAIR (sotatercept) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sotatercept}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sotatercept_20261116","title":"WINREVAIR (sotatercept) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sotatercept","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
